186386-90-3

Upstream product

• 446-35-5 2,4-Difluoronitrobenzene 
• 446-36-6 5-fluoro-2-nitrophenol 
• 186386-91-4 4-fluoro-1-nitro-2-(2,2,2-trifluoroethoxy)benzene 

Downstream Products

• 186385-74-0 3-(3-{4-[4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-5-hydroxymethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrimidine-2,4-dione 
• 592527-68-9 5-ethyl-3-(3-{4-[4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrimidine-2,4-dione 
• 186385-81-9 3-(3-{4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)-5-dimethylamino-1-[2-(trimethylsilyl)ethoxymethyl]-2,4(1H,3H)-pyrimidinedione 
• 186385-78-4 3-(3-{4-[4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrimidine-2,4-dione 
• 186385-77-3 3-(3-{4-[4-fluoro-2-(2,2,2-trifluoroethoxy)-phenyl]piperazin-1-yl}propyl)-5-chloro-1-[2-(trimethylsilyl)ethoxymethyl]-2,4(1H,3H)-pyrimidinedione 
• 186385-71-7 3-(3-{4-[4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrimidine-2,4-dione 
• 592527-71-4 1-benzyl-3-(3-{4-[4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 186386-21-0 RS 100975 
• 186388-11-4 1-(3-chloro-propyl)-4-[4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazine 
• 186387-05-3 1-[4-fluoro-2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 

Relevant academic research and scientific papers

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

Synthesis, pharmacology and pharmacokinetics of 3-(4-Arylpiperazin-1-ylalkyl)-uracils as uroselective α1A-antagonists

Predominance in the urethra and prostate of the α1A-adrenoceptor subtype, which is believed to be the receptor mediating noradrenaline induced smooth muscle contraction in these tissues, led to the preparation of α1A-selective antagonists to be tested as uroselective compounds for the treatment of benign prostatic hyperplasia. Thus, a number of selective α1A-adrenoceptor antagonists were synthesized and assayed in vitro for potency and selectivity. Dog pharmacokinetic parameters of 12 (RO700004) and its metabolite 40 (RO1104253) were established. The relative selectivity of intravenously administered 12, 40 and standard prazosin to inhibit hypogastric nerve stimulation-induced increases in intraurethral prostatic pressure versus phenylephrine-induced increases in diastolic blood pressure in anesthetized dogs was 76, 71 and 0.6, respectively.